Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
4
×
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
4
×
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
fda
regeneron pharmaceuticals
alirocumab
amgen
clinical trials
alder biopharmaceutical
alex azar
allergan
alnylam pharmaceuticals
ambys medicines
american academy of neurology
american patients first
amicus therapeutics
What
drug
4
×
drugs
4
×
fda
long
new
prices
afternoon
anticipated
approval
aren’t
arguments
awaited
big
bio
blueprint
cholesterol
class
commercialized
companies
competitors
cost
cut
decades
details
developers
expensive
faces
financial
foe
gene
healthcare
help
hint
house
imminent
inhibitors
known
lower
lowering
make
Language
unset
Current search:
" raleigh-durham blog main "
×
drugs
×
drug
×
" life sciences "
×
@xconomy.com
5 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
6 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
6 years ago
Trump Pledges Lower Drug Prices, But Blueprint Is Short on Details